ArticlePCN reports : psychiatry and clinical neurosciences2025
Impact of antipsychotics, antiparkinsonian drugs, and anthraquinone stimulant laxatives on severe constipation in patients with schizophrenia.
Article in PCN reports : psychiatry and clinical neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of antipsychotics, antiparkinsonian drugs, and anthraquinone stimulant laxatives on severe constipation in patients with schizophrenia.PCN reports : psychiatry and clinical neurosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Constipation in schizophrenia patients receiving antipsychotics can lead to severe intestinal complications, such as paralytic ileus or megacolon. Despite the clinical importance of the topic, few studies have thoroughly investigated the risk factors of constipation-related complications. Therefore, the present study aimed to identify clinical and pharmacological factors associated with severe, constipation-related conditions in patients with schizophrenia. Methods: The present, retrospective study analyzed inpatients with schizophrenia and constipation at Tokyo Metropolitan Matsuzawa Hospital between 2014 and 2018. Logistic regression analysis was performed to test for any association between severe, constipation-related conditions and patient demographics and the use of various antipsychotics, antiparkinsonian drugs, and anthraquinone stimulant laxatives. Results: Of the 4114 patients included, 556 had a severe, constipation-related condition. High dosages of clozapine (odds ratio [OR]: 8.688; 95% confidence interval [CI]: 1.926-39.186; Conclusion: These findings highlighted the need for careful monitoring of constipation and for optimizing antipsychotic drug regimens. The use of antiparkinsonian drugs and anthraquinone stimulant laxatives should be limited to the short term.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.